Building a Weight Loss Program with Compounded GLP-1s: A Practice Guide

Weight management built on compounded incretins was, for a period, one of the fastest programs a practice could stand up. That period ended, and a number of practices discovered their entire program rested on a regulatory allowance they had not examined.

This covers where things actually stand and how to build something that does not collapse when a position changes.

What Changed, Precisely

Compounded semaglutide and tirzepatide were broadly available under Section 503A because both were listed on the FDA's drug shortage list. Shortage listing is what permits compounding a preparation that would otherwise be prohibited as essentially a copy of a commercially available drug.

When the FDA declared those shortages resolved, that basis narrowed sharply. Compounding an essentially-a-copy preparation outside a shortage is generally not permitted — with one narrow exception: where a prescriber documents a clinically significant difference for a specific patient.

That exception is genuinely narrow. It means a documented, patient-specific clinical reason the commercial product is unsuitable — an allergy to an inactive ingredient, or a dose that cannot be achieved with the commercial product. It is not a general workaround, and using it as one is the exposure a lot of practices are currently carrying.

Our compounded tirzepatide analysis covers the detail.

Retatrutide Is a Different Situation Entirely

Retatrutide is investigational. It is not FDA-approved for any indication, is not a component of an approved drug, has no applicable USP monograph, and is not on the 503A Bulks List.

There is no clear lawful pathway for 503A compounding of it. A supplier advertising it is operating outside sanctioned territory, and several marketing it are not pharmacies at all. Our retatrutide access and legality analysis covers this.

Patient demand for it is real and growing. That is not a reason to supply it.

Building Something Durable

Do Not Build on One Molecule

The practices that got hurt had programs that were, structurally, a single compounded product plus a consultation. When the basis for that product narrowed, the program had nothing underneath it.

A durable program treats the pharmacological agent as one component among several.

The Components Worth Having

The Lean Mass Point

This is the clinical differentiator most programs skip. Rapid incretin-driven weight loss includes a substantial proportion of lean tissue. In perimenopausal and older patients — a large share of who presents — that compounds an existing loss.

Protein targets and resistance training are not adjunct advice. They are part of the protocol, they materially change outcomes, and no regulatory change can take them away from you.

Operational Realities

Titration schedules generate contact. That is a retention advantage if you staff for it and a service failure if you do not.

GI side effects generate calls. Someone must own that queue.

Supply continuity matters more here than anywhere else. A patient mid-titration whose refill cannot be filled is a clinical problem, not just an inconvenience. This is the single strongest argument for a pharmacy partner that flags regulatory changes in advance.

Restored fertility is a real counselling obligation. Weight loss and improved insulin sensitivity can restore ovulation in patients who were not previously ovulating. Patients not seeking pregnancy need contraceptive counselling, and incretins are generally discontinued before conception.

What to Ask Your Pharmacy Partner

• On what basis are you currently compounding this preparation?
• What will you tell me before a position changes, and how far ahead?
• What is your documentation requirement for a clinically significant difference?
• Which alternatives can you supply if this becomes unavailable?
• What analytical testing accompanies each lot?

A partner that cannot answer the first question specifically is one to reconsider. Our verification checklist covers the wider due diligence.

Frequently Asked Questions

Is compounded semaglutide or tirzepatide still available?

The broad basis — shortage listing — ended when the FDA declared those shortages resolved. Compounding is generally not permitted outside a shortage for a preparation that is essentially a copy, except where a prescriber documents a clinically significant difference for a specific patient.

What counts as a clinically significant difference?

A documented, patient-specific reason the commercial product is unsuitable — an excipient allergy, or a dose unachievable with the commercial product. It is a narrow exception, not a general workaround.

Can I offer compounded retatrutide?

Retatrutide is investigational, is not a component of any approved drug, and is not on the 503A Bulks List, so there is no clear lawful compounding pathway. Suppliers offering it are operating outside sanctioned territory.

How do I protect a program from regulatory change?

Do not build it on a single molecule. Evaluation, lab work, nutrition and training protocols, monitoring, and alternative mechanisms all persist regardless of any one compound's status.

Why does lean mass matter in a weight program?

Rapid incretin-driven loss includes substantial lean tissue, which compounds age- and menopause-related loss in many patients who present. Protein targets and resistance training measurably change outcomes and are part of the protocol.

What should I ask a pharmacy before building a program around them?

What their current compounding basis is for the specific preparation, how far in advance they will flag a change, what documentation they require, and what alternatives they can supply.